Risk factor
Very high price volatility
Profitability factor
Favourable price performance
About
AVVAA World Health Care Products, Inc. operates as a global biotechnology firm, specializing in natural and therapeutic personal care solutions. Its primary endeavor involves the development, manufacturing, and mass-market distribution of the over-the-counter Neuroskin product line. These treatments are formulated to address various skin irregularities and promote the natural clarity and texture of healthy skin, reaching consumers through conventional food and drug channels. Beyond its own brands, AVVAA also possesses distribution rights for a range of patented European skincare items. These scientifically-backed formulations target the symptoms of persistent dermatological conditions such as eczema, psoriasis, and acne. Diversifying its portfolio, the company extends its natural care offerings to animals, providing grooming treatments for a variety of pets including dogs, cats, and horses. Established in 1998 and headquartered in Richmond, Virginia, AVVAA has been a subsidiary of Gold Quest Capital, Inc. since June 23, 2021.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is overvalued on EV/EBITDA, overpriced on P